Compare CLM & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLM | RARE |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 1995 | 2013 |
| Metric | CLM | RARE |
|---|---|---|
| Price | $7.43 | $26.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $59.10 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $37.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $6.92 | $18.29 |
| 52 Week High | $8.53 | $39.98 |
| Indicator | CLM | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 65.07 |
| Support Level | $7.33 | $21.54 |
| Resistance Level | $7.79 | $27.42 |
| Average True Range (ATR) | 0.11 | 1.23 |
| MACD | -0.02 | 0.43 |
| Stochastic Oscillator | 7.47 | 85.08 |
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, Consumer Staples, utilities, energy, Real Estate, materials, and other sectors.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.